Andrew Buresh, MD
Hematology & Oncology · Scottsdale, AZNPI 1902870959
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.0% of the total across 113 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,823 and has fallen 99.0% since, to $19 in 2025. That places this record below the midpoint for hematology & oncology clinicians in AZ, where the typical reported total is $6,870.
Across 113 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$358
- Merck$246
- Genentech USA, Inc.$150
- AstraZeneca$126
- Sanofi$123
- Pfizer$112
- plus $943 from 23 others
What the payments were for
- Food & beverage$1,87591%
- Education$1849%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 18 | $358 |
| Merck | 15 | $246 |
| Genentech USA, Inc. | 9 | $150 |
| AstraZeneca(2 entities) | 7 | $126 |
| Sanofi | 8 | $123 |
| Pfizer | 10 | $112 |
| Seagen Inc. | 2 | $92 |
| Bayer | 5 | $87 |
| E.r. Squibb & Sons, L.L.C. | 5 | $86 |
| Novartis | 5 | $80 |
| Amgen | 4 | $78 |
| Exelixis Inc. | 3 | $74 |
| Puma Biotechnology, Inc. | 2 | $48 |
| Daiichi Sankyo Inc. | 2 | $46 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $43 |
| Sun Pharmaceutical Industries Inc. | 1 | $39 |
| Helsinn Therapeutics (U.S.), Inc. | 2 | $30 |
| Telix Pharmaceuticals | 1 | $28 |
| Gilead(2 entities) | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Tesaro, Inc. | 1 | $23 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Lexicon Pharmaceuticals, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $19 |
| Boston Scientific | 1 | $19 |
| Spectrum Pharmaceuticals Inc. | 1 | $17 |
| AbbVie | 1 | $16 |
| Lilly USA, LLC | 1 | $14 |
| Verastem, Inc. | 1 | $12 |
How this compares
$2,059 in reported general payments places this provider in the 30th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 39 | $816,239 |
| CalquenceAcalabrutinib Maleate | 39 | $479,118 |
| Lenalidomide | 27 | $438,914 |
| VerzenioAbemaciclib | 30 | $425,902 |
| JakafiRuxolitinib Phosphate | 24 | $394,756 |
| PomalystPomalidomide | 15 | $390,414 |
| ImbruvicaIbrutinib | 25 | $311,496 |
| EliquisApixaban | 114 | $91,310 |
| XareltoRivaroxaban | 71 | $78,628 |
| Abiraterone Acetate | 27 | $32,842 |
| Letrozole | 84 | $2,237 |
| Hydroxyurea | 99 | $1,104 |
| Tamoxifen Citrate | 23 | $865 |
| Anastrozole | 43 | $781 |
| ValacyclovirValacyclovir Hcl | 20 | $450 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $126 | $479,11839 claims |
| Lilly USA, LLCVerzenio | $14 | $425,90230 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $86 | $390,41415 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $43 | $311,49625 claims |
| PfizerEliquis | $112 | $91,310114 claims |
| Johnson & JohnsonXarelto | $358 | $78,62871 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 261 hematology & oncology providers in Arizona.
Other hematology & oncology in Scottsdale
- Jeffrey SchriberScottsdale$715K
- Tanios Bekaii-SaabScottsdale$527K
- Rajesh KukunoorScottsdale$499K
- Yousef ZakhariaScottsdale$214K
- Thai HoScottsdale$190K
- Alan BryceScottsdale$157K
- Daniel AhnScottsdale$91K
- Brendan CurleyScottsdale$87K
- Alexander StewartScottsdale$76K
- Saurabh ChhabraScottsdale$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.